FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010638846> ?p ?o ?g. }

• W2010638846 endingPage "113" @default.
• W2010638846 startingPage "103" @default.
• W2010638846 abstract "Journal of Clinical Pharmacy and TherapeuticsVolume 8, Issue 2 p. 103-113 THERAPEUTIC PROGRESS—REVIEW VIII DO THE NEWER CYTOTOXIC DRUGS REPRESENT A SIGNIFICANT ADVANCE IN THE TREATMENT OF CANCER? S. Rolf Smith, Corresponding Author S. Rolf Smith Department of Clinical Pharmacology2 Correspondence: Dr S. Rolf Smith.Search for more papers by this authorG. Blackledge, G. Blackledge *Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, BirminghamSearch for more papers by this author S. Rolf Smith, Corresponding Author S. Rolf Smith Department of Clinical Pharmacology2 Correspondence: Dr S. Rolf Smith.Search for more papers by this authorG. Blackledge, G. Blackledge *Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, BirminghamSearch for more papers by this author First published: April 1983 https://doi.org/10.1111/j.1365-2710.1983.tb01039.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Barker, D.J.P. & Rose, G. (1976) Epidemiology in Medical Practice. Churchill Livingstone, Edinburgh . 2 Waterhouse, J.A.H. (1974) Cancer handbook of epidemiology and prognosis. Churchill Livingstone, Edinburgh . 3 Palmer, B.V., Walsh, E.A., McKinna, J.A. & Greening, W.P. (1980) Adjuvant chemotherapy for breast cancer: side-effects and quality of life. British Medical Journal, 281, 1594– 1597. 4 Lerner, H.J. (1978) Acute myelogenous leukaemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treatment Reports, 62, 1135– 1138. 5 Reimer, R.R., Hoover, R., Fraumeni, J.F. & Young, R.C. (1977) Acute leukaemia after alkylating-agent therapy of ovarian cancer. New England Journal of Medicine, 297, 177– 181. 6 Valagussa, P., Santoro, A., Kenda, R., Bellani, F.F., Franchi, F., Banfi, A., Rilke, F. & Bonadonna, G. (1980) Second malignancies in Hodgkin's disease: a complication of certain forms of treatment. British Medical Journal, 280, 216– 219. 7 Zwelling, L.A. & Kohn, K.W. (1979) Mechanism of action of cis-dichlorodiammineplatinum (II). Cancer Treatment Reports, 63, 1439– 1444. 8 Rosenberg, B., Van Camp, L. & Krigas, T. (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 205, 698– 699. 9 Rosenberg, B., Van Camp, L., Trosko, J.E. & Mansow, V.H. (1969) Platinum compounds: a new class of potent antitumour agents. Nature, 222, 385– 386. 10 Samuels, M.L. & Howe, C.D. (1970) Vinblastine in the management of testicular cancer. Cancer, 25, 1009– 1017. 11 Blum, R.H., Carter, S.K. & Agre, K. (1973) A clinical review of bleomycin—a new antineoplastic agent. Cancer, 31, 903– 914. 12 Higby, D.J., Wallace, H.J., Albert, D.J. & Holland, J.F. (1974) Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumours. Cancer, 33, 1219– 1225. 13 Einhorn, L.H. & Donohue, J. (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Annals of Internal Medicine, 87, 293– 298. 14 Williams, S.D. & Einhorn, L.H. (1982) Cis-platinum in the treatment of testicular and other cancers. In: Advances in Internal Medicine. Vol. 27. Year Book Medical Publishers, London . 15 Prestayko, A.W., D'Aoust, J.C., Issell, B.F. & Crooke, S.T. (1979) Cisplatin (cis-diamminedichloroplatinum II). Cancer Treatment Reviews, 6, 17– 39. 16 Einhorn, L.H. & Williams, S.D. (1980) Chemotherapy of disseminated testicular cancer. Cancer, 46, 1339– 1344. 17 Einhorn, L., Williams, S., Turner, S., Troner, M. & Greco, F.A. (1981) The role of maintenance therapy in disseminated testicular cancer: a South Eastern Cancer Study Group (SECGS) protocol. Proceedings of the American Society of Clinical Oncology, 22, 463 (abstract). 18 Smith, J.P. & Rutledge, F. (1970) Chemotherapy in the treatment of cancer of the ovary. American Journal of Obstetrics and Gynecology, 107, 691– 700. 19 Young, R.C. (1975) Chemotherapy of ovarian cancer: past and present. Seminars in Oncology, 2, 267– 276. 20 Young, R.C. (1979) Ovarian carcinoma: an optimistic epilogue. Cancer Treatment Reports, 63, 333– 337. 21 Wiltshaw, E. & Kroner, T. (1976) Phase II study of cis-dichlorodiammineplatinum (II) in advanced adenocarcinoma of the ovary. Cancer Treatment Reports, 60, 55– 60. 22 Ehrlich, C.E., Einhorn, L., Williams, S.D. & Morgan, J. (1979) Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum (II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treatment Reports, 63, 281– 288. 23 Ehrlich, C.E., Einhorn, L.H., Stehman, F.B. & Roth, L. (1980) Response, ‘second-look’ status and survival in stage III-IV epithelial ovarian cancer treated with cis-dichlorodiammineplatinum (II) (cis-platinum), adriamycin, (ADR) and cyclophosphamide (CTX). Proceedings of the American Society of Clinical Oncology, 21, 423 (Abstract). 24 Sturgeon, J.F.G., Fine, S., Gospodarowicz, M.K., Dembo, A.J., Bean, H.A., Bush, R.S., Beale, F.A., Pringle, J.F., Thomas, G.M. & Herman, J.G. (1982) A randomized trial of melphalan alone versus combination chemotherapy in advanced ovarian cancer. Proceedings of the American Society of Clinical Oncology, 1, 108 (Abstract). 25 Vogl, S.E., Kaplan, B. & Pagans, M. (1982) Diamminedichloroplatinum-based combination chemotherapy is superior to melphalan for advanced ovarian cancer when age is 50 and tumour diameter 2cm. Proceedings of the American Society of Clinical Oncology, 1, 119 (Abstract). 26 Yagoda, A., Watson, R.C., Gonzalez-Vitale, J.C., Grabstald, H. & Whitmore, W.F. (1976) Cis-dichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treatment Reports, 60, 917– 923. 27 Yagoda, A., Watson, R.C., Kemeny, N., Barzell, W.E., Grabstald, H. & Whitmore, W.F. (1978) Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer. Cancer, 41, 2121– 2130. 28 Williams, S.D., Einhorn, L.H. & Donohue, J.P. (1979) Cis-platinum combination chemotherapy of advanced bladder cancer: an update. Cancer Clinical Trials, 2, 335. 29 Yagoda, A., Watson, R.C., Natale, R.B., Barzell, W., Sogani, P., Grabstald, H. & Whitmore, W.F. (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedi-chloride platinum II. Cancer, 44, 1553– 1562. 30 Wittes, R., Heller, K., Randolph, V., Howard, J., Vallejo, A., Farr, H., Harrold, C., Gerold, F., Shah, J., Spiro, R. & Strong, E. (1979) Cis-dichlorodiammineplatinum (II)—based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treatment Reports, 63, 1533– 1538. 31 Hong, W.K., Shapshay, S.M., Bhutani, R., Craft, M.L., Vemakli, A., Yamaguchi, K.T., Vaughan, C.W. & Strong, M.S. (1979) Induction chemotherapy in advanced squamous head and neck carcinoma with high-dose cis-platinum and bleomycin infusion. Cancer, 44, 19– 25. 32 Freeman, A.I., Ettinger, L.J. & Brecher, M.L. (1979) Cis-dichlorodiammineplatinum (II) in childhood cancer. Cancer Treatment Reports, 63, 1615– 1620. 33 Ettinger, L.J., Douglass, H.O., Higby, D.J., Mindell, E.R., Nime, F., Ghoorah, J. & Freeman, A.I. (1981) Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma. Cancer, 47, 248– 254. 34 Rosen, G., Huvos, A.G., Nirenberg, A. & Caparros, B.J. (1981) Osteogenic sarcoma: selection of adjuvant chemotherapy based upon the response of the primary tumour to preoperative chemotherapy. Proceedings of the American Society of Clinical Oncology, 22, 429 (Abstract). 35 Nathanson, L., Kaufman, S.D. & Carey, R.W. (1980) Vinblastine-bleomycin-platinum (VBD): a high response rate regimen in metastatic melanoma. Proceedings of the American Society of Clinical Oncology, 21, 479 (Abstract). 36 King, L.S. & Sullivan, M. (1946) The similarity of the effect of podophyllin and colchicine and their use in the treatment of condylomata acuminata, Science, 104, 244– 245. 37 Loike, J.D. & Horwitz, S.B. (1976) Effects of podophyllotoxin and VP-16–213 on microtubule assembly in vitro and nucleoside transport in Hela cells. Biochemistry, 15, 5435– 5443. 38 Loike, J.D., Brewer, C.F., Sternlicht, H., Gensler, W.J. & Horwitz, S.B. (1978) Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Research, 38, 2688– 2693. 39 Schmoll, H. (1982) Review of etoposide single-agent activity. Cancer Treatment Reviews, 9 (suppl. A), 21– 30. 40 Goldhirsch, A., Joss, R., Cavalli, F. & Brunner, K.W. (1982) Etoposide as single agent and in combination chemotherapy of bronchogenic carcinoma. Cancer Treatment Reviews, 9, (suppl. A) 85– 90. 41 Natale, R.B. & Wittes, R.E. (1982) Combination cis-platinum and etoposide in small-cell lung cancer. Cancer Treatment Reviews, 9 (suppl. A), 91– 94. 42 Havemann, K. (1982) Combination chemotherapy of small-cell bronchogenic carcinoma with etoposide (VP-16), ifosfamide and vindesine (VPIV), and with adriamycin, cis-platinum and vincristine (APO). Cancer Treatment Reviews, 9 (suppl. A), 95– 100. 43 Niederle, N., Krischke, W., Bremer, K., Schmidt, C.G. & Seeber, S. (1982) Small-cell bronchogenic carcinoma-primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU. Cancer Treatment Reviews, 9, (suppl. A) 101– 105. 44 Itri, L.M. & Gralla, R.J. (1982) A review of etoposide in patients with non-small-cell lung cancer (NSCLC). Cancer Treatment Reviews, 9 (suppl. A), 115– 118. 45 Cavalli, F. & Joss, R. (1981) Cis-platinum and etoposide (DDP/VP16–213) in the treatment of non-small-cell lung cancer. Proceedings of the International Symposium, New Drugs for Cancer Therapy in the Eighties, Rome, 1981). 46 Klastersky, J., Longeval, E., Nicaise, C. & Weerts, D. (1982) Etoposide and cis-platinum in non-small-cell bronchogenic carcinoma, Cancer Treatment Reviews, 9 (suppl. A), 133– 138. 47 Kroner, T., Obrecht, J.P. & Jungi, W.F. For the Swiss Working Group for Clinical Cancer Research (SAKK) (1982) Etoposide as single agent and in combination with cis-platinum for malignant lymphomas. Cancer Treatment Reviews, 9 (suppl. A), 39– 43. 48 Santoro, A., Bonfante, V. & Bonadonna, G. (1982) Third line chemotherapy with CCNU, etoposide and prednimustine (CEP) in Hodgkin's disease resistant to MOPP and ABVD. Proceedings of the American Society of Clinical Oncology, 1, 165 (Abstract). 49 Rivera, G., Bowman, W.P., Look, A.T., Evans, W.E., Kalwinsky, D. & Dahl, G.V. (1982) Single-agent and combination chemotherapy with etoposide in the acute leukaemias of childhood. Cancer Treatment Reviews, 9 (suppl. A), 53– 57. 50 Williams, S.D. & Einhorn, L.H. (1982) Etoposide salvage therapy for refractory germ cell tumors: an update. Cancer Treatment Reviews, 9 (suppl. A), 67– 71. 51 Hayes, D.M., Cvitkovic, E., Golbey, R.B., Scheiner, E., Helson, L. & Krakoff, I.H. (1977) High dose cis-platinum diammine dichloride. Cancer, 39, 1372– 1381. 52 Calvert, A.H., Harland, S.J., Newell, D.R., Siddik, Z.H., Jones, A., McElwain, T.J., Raju, S., Wiltshaw, E., Smith, I.E., Peckham, M.J., Baker, J. & Harrap, K.R. (1982) Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Proceedings of the American Association for Cancer Research, 23, 129 (Abstract). Volume8, Issue2April 1983Pages 103-113 ReferencesRelatedInformation" @default.
• W2010638846 created "2016-06-24" @default.
• W2010638846 creator A5055000599 @default.
• W2010638846 creator A5078201837 @default.
• W2010638846 date "1983-04-01" @default.
• W2010638846 modified "2023-09-25" @default.
• W2010638846 title "THERAPEUTIC PROGRESS—REVIEW VIII DO THE NEWER CYTOTOXIC DRUGS REPRESENT A SIGNIFICANT ADVANCE IN THE TREATMENT OF CANCER?" @default.
• W2010638846 cites W1485479681 @default.
• W2010638846 cites W1970133810 @default.
• W2010638846 cites W1980411311 @default.
• W2010638846 cites W1988085635 @default.
• W2010638846 cites W2012108057 @default.
• W2010638846 cites W2013042376 @default.
• W2010638846 cites W2020929943 @default.
• W2010638846 cites W2024161468 @default.
• W2010638846 cites W2031209163 @default.
• W2010638846 cites W2033022308 @default.
• W2010638846 cites W2037913931 @default.
• W2010638846 cites W2039327157 @default.
• W2010638846 cites W2039784427 @default.
• W2010638846 cites W2041334348 @default.
• W2010638846 cites W2046385603 @default.
• W2010638846 cites W2052788340 @default.
• W2010638846 cites W2055154319 @default.
• W2010638846 cites W2057336215 @default.
• W2010638846 cites W2057410205 @default.
• W2010638846 cites W2060372099 @default.
• W2010638846 cites W2071879792 @default.
• W2010638846 cites W2075741662 @default.
• W2010638846 cites W2078710130 @default.
• W2010638846 cites W2079449139 @default.
• W2010638846 cites W2087307665 @default.
• W2010638846 cites W2089349406 @default.
• W2010638846 cites W2093544927 @default.
• W2010638846 cites W2094863604 @default.
• W2010638846 cites W2336358779 @default.
• W2010638846 doi "https://doi.org/10.1111/j.1365-2710.1983.tb01039.x" @default.
• W2010638846 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6348098" @default.
• W2010638846 hasPublicationYear "1983" @default.
• W2010638846 type Work @default.
• W2010638846 sameAs 2010638846 @default.
• W2010638846 citedByCount "0" @default.
• W2010638846 crossrefType "journal-article" @default.
• W2010638846 hasAuthorship W2010638846A5055000599 @default.
• W2010638846 hasAuthorship W2010638846A5078201837 @default.
• W2010638846 hasBestOaLocation W20106388461 @default.
• W2010638846 hasConcept C121608353 @default.
• W2010638846 hasConcept C126322002 @default.
• W2010638846 hasConcept C143998085 @default.
• W2010638846 hasConcept C177713679 @default.
• W2010638846 hasConcept C71924100 @default.
• W2010638846 hasConceptScore W2010638846C121608353 @default.
• W2010638846 hasConceptScore W2010638846C126322002 @default.
• W2010638846 hasConceptScore W2010638846C143998085 @default.
• W2010638846 hasConceptScore W2010638846C177713679 @default.
• W2010638846 hasConceptScore W2010638846C71924100 @default.
• W2010638846 hasIssue "2" @default.
• W2010638846 hasLocation W20106388461 @default.
• W2010638846 hasLocation W20106388462 @default.
• W2010638846 hasOpenAccess W2010638846 @default.
• W2010638846 hasPrimaryLocation W20106388461 @default.
• W2010638846 hasRelatedWork W1583511338 @default.
• W2010638846 hasRelatedWork W2224319365 @default.
• W2010638846 hasRelatedWork W2365364931 @default.
• W2010638846 hasRelatedWork W2418638721 @default.
• W2010638846 hasRelatedWork W2804884407 @default.
• W2010638846 hasRelatedWork W2989971117 @default.
• W2010638846 hasRelatedWork W3107519578 @default.
• W2010638846 hasRelatedWork W4225136820 @default.
• W2010638846 hasRelatedWork W4252371801 @default.
• W2010638846 hasRelatedWork W4324259137 @default.
• W2010638846 hasVolume "8" @default.
• W2010638846 isParatext "false" @default.
• W2010638846 isRetracted "false" @default.
• W2010638846 magId "2010638846" @default.
• W2010638846 workType "article" @default.